| Autor: |
Kim I; Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea., Kim JH; Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea., Kim K; Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea., Seong S; Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea., Lee KB; Department of Orthopedic Surgery, Chonnam National University Medical School and Hospital, Gwangju 61469, Korea., Kim N; Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea. |
| Abstrakt: |
Interferon regulatory factors (IRFs) play roles in various biological processes including cytokine signaling, cell growth regulation and hematopoietic development. Although it has been reported that several IRFs are involved in bone metabolism, the role of IRF2 in bone cells has not been elucidated. Here, we investigated the involvement of IRF2 in RANKL-induced osteoclast differentiation. IRF2 overexpression in osteoclast precursor cells enhanced osteoclast differentiation by regulating the expression of NFATc1, a master regulator of osteoclastogenesis. Conversely, IRF2 knockdown inhibited osteoclast differentiation and decreased the NFATc1 expression. Moreover, IRF2 increased the translocation of NF-κB subunit p65 to the nucleus in response to RANKL and subsequently induced the expression of NFATc1. IRF2 plays an important role in RANKL-induced osteoclast differentiation by regulating NF-κB/NFATc1 signaling pathway. Taken together, we demonstrated the molecular mechanism of IRF2 in osteoclast differentiation, and provide a molecular basis for potential therapeutic targets for the treatment of bone diseases characterized by excessive bone resorption. [BMB Reports 2021; 54(9): 482-487]. |
